Pre-transplant CAR T-cell therapy is associated with inferior survival and increased non-relapse mortality in pediatric B-ALL: A single-center retrospective analysis
Retrospective analysis shows CAR T-cell therapy associates with worse survival and increased non-relapse mortality in pediatric B-ALL, highlighting care needs.
Key Points
To evaluate the impact of pre-transplant CAR T-cell therapy on survival and non-relapse mortality in pediatric patients with B-ALL.
Retrospective analysis of pediatric patients undergoing HSCT for B-ALL
Comparison of outcomes between CAR T-cell therapy and HSCT-only groups
Survival and transplant-related toxicity evaluated using appropriate statistical models
CAR T group demonstrated significantly worse overall survival (66.9% vs 94.4%) and disease-free survival (66.2% vs 91.6%)
Increased non-relapse mortality observed in CAR T recipients (16.8% vs 2.9%)
Higher rates of viral infections were notably more prevalent in CAR T group (26% vs 6%)